BioCryst Pharmaceuticals Inc. Common Stock (BCRX)

FairStock Score: 95/100 — HIGH CONVICTION

Key Financials

Strengths

• Generates $264 million in annual free cash flow (11.9% yield on market cap)
• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Superior net profit margin of 27.8% indicating pricing power and operational efficiency
• Revenue growth of 209.1% demonstrates strong top-line momentum
• FairStock composite score of 95/100 places it in the top tier across value, quality, and momentum factors

Concerns

• Altman Z-Score of 1.0 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

BioCryst Pharmaceuticals Inc. Common Stock is a small-cap healthcare company valued at $2.2 billion. The business generates $886 million in annual revenue with a 27.8% net margin and $264 million in free cash flow. From a quality standpoint, BioCryst shows solid Piotroski F-Score of 7/9 and distressed Altman Z-Score of 1.0 warrants caution. On valuation, the stock is deeply undervalued on a P/E basis at 7.3x, with PEG of 0.01 suggests growth is underpriced. Growth dynamics show revenue growing at 209.1% and profit growth of 1017.5%. Our composite FairStock Score of 95/100 reflects strong fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

BioCryst's 209% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $264 million in annual free cash flow (11.9% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer